Levocetirizine in 1  2 year old children: pharmacokinetic and pharmacodynamic profile

Cranswick, Noel; Turzíkova, J; Fuchs, M; Hulhoven, R.

doi:10.5414/cpp43172

Cited by 27 publications

(10 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, use of the newer H 1 -antihistamines counteracts the feeling of malaise caused by allergic rhinitis and may improve learning ability in allergic rhinitis. Pharmacokinetic studies of the secondgeneration H 1 -antihistamines have been performed on children, but few studies have been carried out on infants (116,(2227)(2228)(2229). Interactions with the cytochrome P450 may reduce the metabolism of the H 1 -antihistamines metabolized in the liver.…”

Section: Treatmentmentioning

confidence: 99%

Allergic Rhinitis and its Impact on Asthma (ARIA) 2008*

Bousquet¹,

Khaltaev²,

Cruz³

et al. 2008

Allergy

3,823

1,761

View full text Add to dashboard Cite

Section: Treatmentmentioning

confidence: 99%

Allergic Rhinitis and its Impact on Asthma (ARIA) 2008*

Bousquet¹,

Khaltaev²,

Cruz³

et al. 2008

Allergy

3,823

1,761

View full text Add to dashboard Cite

“…In the fi rst study of 12-to 24-month-old children, the pharmacokinetic and pharmacodynamic profi les of levocetirizine, 0.125 mg/kg twice a day, were adequate, and the safety profi le was good [39]. The second study was designed to evaluate the safety profi le of levocetirizine, 0.125 mg/kg twice daily over a period of 18 months, in 12-to 24-month-old children [40].…”

Section: Levocetirizinementioning

confidence: 95%

“…Recent studies demonstrated that levocetirizine is safe in young, atopic children [39,40]. In the fi rst study of 12-to 24-month-old children, the pharmacokinetic and pharmacodynamic profi les of levocetirizine, 0.125 mg/kg twice a day, were adequate, and the safety profi le was good [39].…”

Section: Levocetirizinementioning

confidence: 99%

Update on prescription and over-the-counter histamine inverse agonists in rhinitis therapy

DuBuske

Kowal²

2009

Curr Allergy Asthma Rep

View full text Add to dashboard Cite

Allergic rhinitis (AR) is associated with histamine-mediated physiologic events. The currently used histamine antagonists are all inverse agonists that bind and inactivate histamine H1 receptors. Second-generation antihistamines are much more H1-receptor selective with less central nervous system penetration than first-generation agents. Antihistamines typically are more effective in seasonal than perennial AR and do not demonstrate significant relief of nasal congestion. The recent availability of some second-generation antihistamines as over-the-counter products clearly places them as the preferred first-line treatment for mild to moderate AR based on safety when compared with first-generation over-the-counter antihistamines. The remaining prescription-only second-generation antihistamines, fexofenadine, desloratadine, and levocetirizine, all have unique attributes. Antihistamines in oral, intranasal, or intraocular formulations will likely remain among the mainstays of allergy therapeutics.

show abstract

“…36 Additional study using LCZ0.125 mg/kg twice daily in children with mean (SD) age 20.7 (3.7) months and mean (SD) weight 11.6 (1.8) kg reported elimination half-life 4.1 (0.7) hours and clearance 1.05 mL/min/kg. 37 There is increased clearance of LCZ in this age group, possibly requiring higher milligram per kilogram dose and more frequent dosing, as opposed to traditional once-daily dosing, to treat symptoms of AR. 36,37 In children 6-12 years, pharmacokinetic study of LCZ showed mean (SD) elimination half-life 5.7 (0.2) hours and V D 0.4 (0.02 L/kg), supporting once-daily dosing in this age range.…”

Section: Special Populationsmentioning

confidence: 99%

Levocetirizine: Review of its Use in the Treatment of Seasonal Allergic Rhinitis

McLaughlin-Middlekauff

Elrod²

2011

Clinical Medicine Reviews in Therapeutics

View full text Add to dashboard Cite

Background: Levocetirizine (LCZ), the active R-enantiomer of cetirizine, is a second-generation antihistamine approved for symptom treatment due to seasonal allergic rhinitis (SAR), perennial allergic rhinitis, and chronic idiopathic urticaria in patients $6 months of age. Objective: To review available literature about pharmacokinetics, pharmacodynamics, efficacy, tolerability, quality of life, and pharmacoeconomics of LCZ use in adults and children with SAR. Methods: Databases searched were: MEDLINE, CINAHL Plus with Full Text, Cochrane Central Register of Controlled Trials, Cochrane Database of Systematic Reviews, Cochrane Methodology Register, EMBASE, NHS Economic Evaluation Database, and Database of Abstracts of Reviews of Effectiveness. Search terms included levocetirizine, histamine H 1 antagonists-non-sedating, seasonal allergic rhinitis, pregnancy, quality of life, case reports, cost, and pharmacoeconomics. Relevant article reference lists were also used to obtain additional articles. Results: LCZ exhibits rapid and extensive absorption, high affinity/selectivity for H 1 receptor, and rapid onset and long duration of action. Eight articles assessing clinical efficacy were reviewed. In 4 placebo-controlled studies, LCZ 5 mg/day significantly reduced nasal symptoms in 3 studies and had similar efficacy in 1 study. LCZ was more effective in reducing SAR symptoms vs. desloratadine 5 mg/day but not vs. rupatadine (RUP) 10 mg/day, and RUP was more effective than LCZ in reducing nasal symptoms (P = 0.02). Addition of LCZ 5 mg/day to fluticasone nasal spray therapy improved nasal blockage symptoms only (P , 0.005). Studies investigating anti-inflammatory effects produced inconsistent results. LCZ was not associated with serious adverse events and is generally well tolerated with complaints of somnolence and fatigue; also, there was an increase in febrile seizures in infants. Conclusion: LCZ is an effective and well-tolerated second-generation antihistamine used for the treatment of SAR in adults and children, but its effects on inflammatory markers and performance versus other treatment options require further investigation.

show abstract

Levocetirizine in 1 2 year old children: pharmacokinetic and pharmacodynamic profile

Cited by 27 publications

References 0 publications

Allergic Rhinitis and its Impact on Asthma (ARIA) 2008*

Allergic Rhinitis and its Impact on Asthma (ARIA) 2008*

Update on prescription and over-the-counter histamine inverse agonists in rhinitis therapy

Levocetirizine: Review of its Use in the Treatment of Seasonal Allergic Rhinitis

Contact Info

Product

Resources

About

Levocetirizine in 1  2 year old children: pharmacokinetic and pharmacodynamic profile

Cited by 27 publications

References 0 publications

Allergic Rhinitis and its Impact on Asthma (ARIA) 2008*

Allergic Rhinitis and its Impact on Asthma (ARIA) 2008*

Update on prescription and over-the-counter histamine inverse agonists in rhinitis therapy

Levocetirizine: Review of its Use in the Treatment of Seasonal Allergic Rhinitis

Contact Info

Product

Resources

About

Levocetirizine in 1 2 year old children: pharmacokinetic and pharmacodynamic profile